MLS Capital Fund II LP - 24 Jul 2023 Form 4 Insider Report for GreenLight Biosciences Holdings, PBC

Role
Other*
Signature
MLS Capital Fund II, L.P., By: MLSCF II (GP) (Labuan), LLP, Its: General Partner, By: /s/ Ganesh Kishore, Title: Manager
Issuer symbol
N/A
Transactions as of
24 Jul 2023
Net transactions value
$0
Form type
4
Filing time
26 Jul 2023, 20:34:12 UTC
Previous filing
26 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GRNA Common Stock, par value $0.0001 per share Other -5,818,575 -100% 0 24 Jul 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Contribution and Exchange Agreement dated May 29, 2023 between GreenLight Biosciences Parent, PBC ("Parent") and MLS Capital Fund II, L.P., MLS Capital Fund II, L.P. contributed its shares of common stock of the Issuer to Parent in exchange for shares of Series A-2 Preferred Stock, par value $0.0001 per share, of Parent in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated May 29, 2023, by and among Issuer, Parent and SW MergerCo, Inc. ("Merger Sub") on July 24, 2023, pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent.

Remarks:

The Reporting Person may be deemed to be members of a "group" (within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934 of persons that, in the aggregate, beneficially owned more than 10% of the Issuer's Common Stock. The filing of this Form 4 shall not be construed as an admission that the Reporting Person was a beneficial owner of more than 10% of any class of securities of the Issuer for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.